Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Safety Study of MGD006 in Relapsed / Refractory Acute Myeloid Leukemia (AML) or Intermediate-2 / High Risk MDS

Multiple Cancer Types

The primary goal of this Phase 1 / 2, dose-escalation study, is to determine the maximum tolerated dose level of flotetuzumab (MGD006) in patients with AML whose disease is not expected to benefit from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in the body (pharmacokinetics [PK], pharmacodynamics) and to evaluate potential anti-tumor activity of flotetuzumab.
Leukemia, Myelodysplastic Syndrome, Phase I
I/II
Byrne, Michael
NCT02152956
VICCHEMP1828

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: